# Understanding and optimizing antibody-based interventions against neonatal HSV infection

> **NIH NIH R01** · DARTMOUTH COLLEGE · 2024 · $785,011

## Abstract

ABSTRACT
 The fetal/neonatal period represents a unique period of vulnerability to viral infections. While
Herpesviruses such as herpes simplex virus (HSV) are highly prevalent and typically non life-threatening
infections among healthy adults, they are among the most consequential viral infections of early life. HSV
infection during parturition or the early postnatal period results in disseminated disease or encephalitis in up to
50% of infected newbowns. Without treatment, mortality is high and an estimated 70% of surviving infants with
central nervous system (CNS) involvement suffer long-term neurodevelopmental sequelae despite aggressive
treatment with acyclovir. Fortunately, newborns in our pathogen-rich world inherit some of the protection provided
by the maternal immune system in the form of transferred antibodies (Ab). For HSV, maternal Ab seropositivity,
resulting in placental transfer of Ab capable of directly neutralizing virus and eliciting the diverse effector functions
of the innate immune system, is associated with dramatically decreased risk of nHSV.
 There is no currently approved HSV vaccine whereby maternal Abs could be induced among
seronegative mothers. As an alternative, our previous work has demonstrated that maternal Ab readily accesses
neural tissues of the fetus and is sufficient to prevent nHSV. Preliminary data now demonstrate a novel mouse
model system whereby we can model not only mortality and viral burden, but also behavioral pathologies that
are frequent and lifelong in humans following nHSV. The central hypothesis of this proposal is that the
development of effective vaccines and therapeutic antibodies for nHSV infections will benefit from careful in vivo
and in vitro evaluation of antibody mechanism(s) of action. Presently, there is a critical gap in knowledge of the
mechanisms whereby Ab-based interventions provide benefit in the context of nHSV infection, and how these
interventions might be optimized in order to best prevent this devastating disease.
 Our objective is to define and refine the means by which monoclonal antibodies (mAbs) can be used
to prevent or reduce nHSV morbidity and mortality. We hypothesize that while Ab effector functions contribute
to direct neutralization activity, they are modulated by the viral Fc Receptor (vFcR), glycoprotein E (gE/gI
complex). Guided by strong preliminary data, the project goals will be achieved though completion of two
Specific Aims: 1) Define the mechanism(s) of action of mAbs that prevent nHSV, and 2) Define the role of the
viral Fc receptor (gE/gI) in influencing antiviral mAb activity.

## Key facts

- **NIH application ID:** 10906996
- **Project number:** 5R01AI176646-02
- **Recipient organization:** DARTMOUTH COLLEGE
- **Principal Investigator:** Margaret E Ackerman
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $785,011
- **Award type:** 5
- **Project period:** 2023-08-14 → 2028-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10906996

## Citation

> US National Institutes of Health, RePORTER application 10906996, Understanding and optimizing antibody-based interventions against neonatal HSV infection (5R01AI176646-02). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10906996. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*